NEW YORK, Aug. 12-Paradigm Genetics today reported increased losses and declining revenues for the second quarter of 2002.
Net loss for the quarter was $5 million or $0.16 per share, compared to a net loss of $4.3 million or $0.16 per share in the same quarter of 2001.
Revenues fell by 13 percent to $5.3 million for the quarter from $6.1 million in the first quarter of 2001, a slump caused by a slowdown in Paradigm's commercial partnership with Bayer. The company said this decline was partly offset by new revenues from its December 2001 purchase of the plant genomics firm ParaGen.
Including stock-based compensation expenses, the company spent $7.6 million on R&D in the quarter, up from $6.9 million in the second quarter last year.
As of June 30, 2002, Paradigm held $9.6 million in cash, cash equivalents and short-term investments.
Earlier this spring, Paradigm launched a house-cleaningthat laid off 20 percent of the workforce and replaced founder and CEO John Ryals with Syngenta executive Heinrich Gugger.